nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

20.02.2024 | Editorial

Advances in targeted alpha therapy of cancer

verfasst von: Mike Sathekge, Alfred Morgenstern

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Excerpt

There is remarkable interest worldwide on the use of targeted alpha therapy on several cancers such as brain tumors, bladder cancer, neuroendocrine tumors, leukemia, and prostate cancer [1]. This rapidly increasing use of alpha-emitting radionuclides is based on the advantages over other forms of radiation due to the shorter path length and high linear energy transfer (LET) of alpha radiation that also leads to the strongly reduced dependency of a damaging effect on oxygenation [1, 2]. …

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with ²²⁵actinium and ²¹³bismuth. Curr Radiopharm. 2018;11(3):200–8.CrossRefPubMedPubMedCentral

Sgouros G, Frey E, Du Y, Hobbs R, Bolch W. Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. Eur J Nucl Med Mol Imaging. 2021;49(1):18–29.CrossRefPubMed

Jalloul W, Ghizdovat V, Stolniceanu CR, Ionescu T, Grierosu IC, Pavaleanu I, Moscalu M, Stefanescu C. Targeted alpha therapy: all we need to know about 225ac’s physical characteristics and production as a potential theranostic radionuclide. Pharmaceuticals (Basel). 2023;16(12):1679. https://doi.org/10.3390/ph16121679.CrossRefPubMed

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802.CrossRefPubMed

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A. ²²5Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.CrossRefPubMed

Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E, Brogsitter C, Kotzerke J, Kopka K, Scheinberg DA, McDevitt MR. Alpha-emitting radionuclides: current status and future perspectives. Pharmaceuticals (Basel). 2024;17(1):76. https://doi.org/10.3390/ph17010076.CrossRefPubMed

Grieve ML, Paterson BM. The evolving coordination chemistry of radiometals for targeted alpha therapy. Aust J Chem. 2022;75:65–88.CrossRef

Eychenne R, Cherel M, Haddad F, Guerard F, Gestin JF. Overview of the most promising radionuclides for targeted alpha therapy: the “Hopeful Eight.” Pharmaceutics. 2021;13:906.CrossRefPubMedPubMedCentral

Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023;24(14):11626. https://doi.org/10.3390/ijms241411626.CrossRefPubMedPubMedCentral

10.

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D’Alessandria C, Morgenstern A, Eiber M. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021;79(3):343–50.CrossRefPubMed

11.

Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekimsoy T, Knoesen O, Kratochwil C. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175–83.CrossRefPubMed

12.

Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Mdlophane A, Maes A, Mokoala K, Mathabe K. mCRPC patients receiving 225Ac-PSMA-617 therapy in the post–androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. 2022;63(10):1496–502.CrossRefPubMedPubMedCentral

13.

Ballal S, Yadav MP, Tripathi M, Sahoo RK, Bal C. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study. J Nucl Med. 2022:jnumed.122.264043. https://doi.org/10.2967/jnumed.122.264043.

14.

Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R. Targeted α-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial. J Nucl Med. 2022;63(9):1326–33.CrossRefPubMedPubMedCentral

15.

Sgouros G. Dosimetry, radiobiology and synthetic lethality: radiopharmaceutical therapy (RPT) with alpha-particle-emitters. Semin Nucl Med. 2020;50(2):124–32.CrossRefPubMedPubMedCentral

Titel: Advances in targeted alpha therapy of cancer
verfasst von: Mike Sathekge
Alfred Morgenstern
Publikationsdatum: 20.02.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06658-1

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Advances in targeted alpha therapy of cancer

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Expanding the clinical indications of [18F]fluorocholine PET/CT in primary hyperparathyroidism: the evidence cannot be evaded

FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis

Effects of medication on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

Correction to: Theranostic role of 89Zr‑ and 177Lu‑labeled aflibercept in breast cancer

Intense PSMA expression of the uvula detected by [68 Ga]Ga-PSMA-PET/CT

Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease